A Patient’s Guide to Clinical Trials
En Español | En Français
NIH Clinical Research Trials and You
Guidance regarding HIV anti-retroviral treatment in developing countries
Policy on Research Involving Human Subjects
Researchers at the National Institutes of Health (NIH) are testing an investigational vaccine for a virus that typically causes symptoms seen in the common cold and flu. The goal of this research study is to learn whether the vaccine is safe, causes a strong immune response, and prevents the virus from spreading to others. This will help researchers develop vaccines for common illnesses.
You may be eligible for the study if you
Participants will be asked to visit the NIH Clinical Center in Bethesda, Maryland, for a blood draw, medical history, and physical exam. Participants will return to NIH to receive the investigational vaccine, which will be given in the back of the throat or as a pill. Participants will need to stay at NIH for up to one week for monitoring. Individuals in close contact with participants may also need to visit NIH; however, they will not receive the vaccine.
The study is being conducted at the Warren Grant Magnuson Clinical Center (Building 10) on the NIH campus in Bethesda, Maryland. The NIH campus is accessible by car and public transportation.
There is no charge to participate in the study. All screening and study-related medical care and procedures are provided free of charge.
Yes, you and any close contacts will be compensated for participation in the study. Transportation and other expenses may also be covered.
To see if you may qualify or for more information, contact
Patient Recruitment and Public Liaison OfficeToll Free: 1-800-411-1222 (reference 11-I-0259/SAMOSA study or 13-I-0081/NAAN study)TTY: 1-866-411-1010 Se habla españolEmail: email@example.com Office hours: 8:00 a.m. – 3:30 p.m. Eastern Time
To learn more about this study of intranasal AD4-H5-VTN as an adenovirus vaccine (trial ID: NCT01806909), please visit clinicaltrials.gov.
Last Updated August 21, 2013
Last Reviewed February 13, 2015